Table_1_Exploring the association between phytopharmaceutical use and antibiotic prescriptions in upper respiratory infections: results from a German cohort study evaluating the im... by Anna-Jasmin Wetzel (17837840)

“…</p>Conclusion<p>Prescriptions of phytopharmaceuticals were significantly associated with a decrease antibiotic prescriptions among GPs, especially when combined with naturopathy qualifications. …”

Image 1_Active ingredients isolated from Periplaneta americana L. inhibit the inflammation of the colonic mucosa and regulate the gut microbiota in DSS-induced ulcerative colitis i... by Yanhuan Wang (12037016)

“…Furthermore, PA treatment attenuated intestinal dysbiosis in UC mice, characterized by an increase in beneficial bacteria (e.g., Psychrobacter) and a decrease in taxa like Actinobacteriota.</p>Conclusion<p>These findings collectively indicate that the aqueous extract of Periplaneta americana L. and its fractions possess significant therapeutic potential for UC treatment, with the unfractionated extract showing the most pronounced benefits via modulating inflammation, restoring barrier function, and rebalancing gut microbiota.…”

Table5_Predicting acute lung injury in infants with congenital heart disease after cardiopulmonary bypass by gut microbiota.xlsx by Lan Jiang (57811)

“…The microbiota diversity was low in the CPB-ALI group with high pathogen abundance and significant decrease in Bacteroides, while the opposite was observed in the CPB-NALI group. …”

Image 2_Active ingredients isolated from Periplaneta americana L. inhibit the inflammation of the colonic mucosa and regulate the gut microbiota in DSS-induced ulcerative colitis i... by Yanhuan Wang (12037016)

“…Furthermore, PA treatment attenuated intestinal dysbiosis in UC mice, characterized by an increase in beneficial bacteria (e.g., Psychrobacter) and a decrease in taxa like Actinobacteriota.</p>Conclusion<p>These findings collectively indicate that the aqueous extract of Periplaneta americana L. and its fractions possess significant therapeutic potential for UC treatment, with the unfractionated extract showing the most pronounced benefits via modulating inflammation, restoring barrier function, and rebalancing gut microbiota.…”

Table4_Predicting acute lung injury in infants with congenital heart disease after cardiopulmonary bypass by gut microbiota.xlsx by Lan Jiang (57811)

“…The microbiota diversity was low in the CPB-ALI group with high pathogen abundance and significant decrease in Bacteroides, while the opposite was observed in the CPB-NALI group. …”

Table1_Predicting acute lung injury in infants with congenital heart disease after cardiopulmonary bypass by gut microbiota.xlsx by Lan Jiang (57811)

“…The microbiota diversity was low in the CPB-ALI group with high pathogen abundance and significant decrease in Bacteroides, while the opposite was observed in the CPB-NALI group. …”

Table 3_Active ingredients isolated from Periplaneta americana L. inhibit the inflammation of the colonic mucosa and regulate the gut microbiota in DSS-induced ulcerative colitis i... by Yanhuan Wang (12037016)

“…Furthermore, PA treatment attenuated intestinal dysbiosis in UC mice, characterized by an increase in beneficial bacteria (e.g., Psychrobacter) and a decrease in taxa like Actinobacteriota.</p>Conclusion<p>These findings collectively indicate that the aqueous extract of Periplaneta americana L. and its fractions possess significant therapeutic potential for UC treatment, with the unfractionated extract showing the most pronounced benefits via modulating inflammation, restoring barrier function, and rebalancing gut microbiota.…”

Image4_Predicting acute lung injury in infants with congenital heart disease after cardiopulmonary bypass by gut microbiota.jpeg by Lan Jiang (57811)

“…The microbiota diversity was low in the CPB-ALI group with high pathogen abundance and significant decrease in Bacteroides, while the opposite was observed in the CPB-NALI group. …”

Image5_Predicting acute lung injury in infants with congenital heart disease after cardiopulmonary bypass by gut microbiota.jpeg by Lan Jiang (57811)

“…The microbiota diversity was low in the CPB-ALI group with high pathogen abundance and significant decrease in Bacteroides, while the opposite was observed in the CPB-NALI group. …”

Table 4_Active ingredients isolated from Periplaneta americana L. inhibit the inflammation of the colonic mucosa and regulate the gut microbiota in DSS-induced ulcerative colitis i... by Yanhuan Wang (12037016)

“…Furthermore, PA treatment attenuated intestinal dysbiosis in UC mice, characterized by an increase in beneficial bacteria (e.g., Psychrobacter) and a decrease in taxa like Actinobacteriota.</p>Conclusion<p>These findings collectively indicate that the aqueous extract of Periplaneta americana L. and its fractions possess significant therapeutic potential for UC treatment, with the unfractionated extract showing the most pronounced benefits via modulating inflammation, restoring barrier function, and rebalancing gut microbiota.…”

Image2_Predicting acute lung injury in infants with congenital heart disease after cardiopulmonary bypass by gut microbiota.jpeg by Lan Jiang (57811)

“…The microbiota diversity was low in the CPB-ALI group with high pathogen abundance and significant decrease in Bacteroides, while the opposite was observed in the CPB-NALI group. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Table 3_Global, regional, and national burden of premenstrual syndrome from 1990 to 2021 and projections to 2050: an analysis based on the 2021 Global Burden of Disease study.xlsx by Ruonan Qiang (22753394)

“…Background<p>Premenstrual syndrome (PMS) imposes significant psychological and mental health burdens on women’s reproductive and general well-being. …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image 1_MLL4 regulates postnatal palate growth and midpalatal suture development.tif by Jung-Mi Lee (14912426)

“…Additionally, SOX9, a master regulator of chondrogenesis, exhibited a significant decrease in protein expression. Indeed, time-course histological analysis during postnatal palate growth revealed retardation in the development of the suture cartilage in Mll4-cKO mice. …”

Data Sheet 1_MLL4 regulates postnatal palate growth and midpalatal suture development.csv by Jung-Mi Lee (14912426)

“…Additionally, SOX9, a master regulator of chondrogenesis, exhibited a significant decrease in protein expression. Indeed, time-course histological analysis during postnatal palate growth revealed retardation in the development of the suture cartilage in Mll4-cKO mice. …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”